Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Sees Significant Growth in Short Interest

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 26,030,000 shares, an increase of 13.5% from the December 15th total of 22,940,000 shares. Based on an average daily trading volume, of 2,170,000 shares, the days-to-cover ratio is currently 12.0 days.

Analyst Ratings Changes

LCTX has been the subject of a number of research analyst reports. Maxim Group dropped their price target on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, January 10th. HC Wainwright lifted their target price on shares of Lineage Cell Therapeutics from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Finally, D. Boral Capital reissued a “buy” rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research note on Friday, January 3rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $4.80.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC lifted its holdings in shares of Lineage Cell Therapeutics by 35.5% during the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after purchasing an additional 18,053 shares during the last quarter. XTX Topco Ltd bought a new position in Lineage Cell Therapeutics during the 2nd quarter valued at approximately $61,000. GSA Capital Partners LLP bought a new position in Lineage Cell Therapeutics during the 3rd quarter valued at approximately $84,000. Rhumbline Advisers raised its stake in Lineage Cell Therapeutics by 15.1% during the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock valued at $132,000 after buying an additional 17,411 shares during the last quarter. Finally, Barclays PLC boosted its holdings in Lineage Cell Therapeutics by 311.3% in the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after acquiring an additional 159,924 shares in the last quarter. Institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Trading Up 2.8 %

Shares of LCTX stock opened at $0.59 on Monday. The firm has a market cap of $129.47 million, a PE ratio of -4.90 and a beta of 1.18. Lineage Cell Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.61.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.